Diabetes mellitus refers to a group of metabolic disorders characterized by chronic hyperglycemia due to impaired insulin secretion, impaired insulin action, or both. The two major categories are type 1 diabetes (autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency) and type 2 diabetes (progressive insulin resistance with relative insulin deficiency). Persistent elevation of blood glucose damages vascular endothelium, alters lipid metabolism, promotes oxidative stress, and triggers inflammatory pathways, which together explain the multisystem complications of diabetes.
In type 2 diabetes, insulin resistance occurs in liver, skeletal muscle, and adipose tissue. Hepatic gluconeogenesis increases, glycogen storage and utilization decrease, and free fatty acid flux to the liver rises, worsening hepatic insulin resistance and driving overproduction of glucose. In peripheral tissues, impaired insulin signaling reduces glucose uptake via GLUT4 transporters. Over time, beta-cell compensation fails, resulting in sustained hyperglycemia. In type 1 diabetes, immune-mediated beta-cell destruction leads to lack of insulin, causing unchecked lipolysis and ketogenesis; this can rapidly progress to diabetic ketoacidosis without prompt insulin replacement.
Clinically, diabetes presents with classic symptoms when hyperglycemia is significant: polyuria, polydipsia, weight loss, fatigue, blurred vision, and recurrent infections. However, many people—especially with type 2 diabetes—are asymptomatic for years, with dysglycemia detected through laboratory screening. Diagnostic criteria typically use HbA1c, fasting plasma glucose, and/or oral glucose tolerance testing. HbA1c reflects average glycemia over approximately 2–3 months and is influenced by hemoglobin turnover, anemia, and certain hemoglobinopathies.
The long-term risk profile is defined by microvascular and macrovascular complications. Microvascular disease includes diabetic retinopathy, nephropathy, and neuropathy. Retinopathy arises from capillary basement membrane thickening, pericyte loss, microaneurysms, ischemia, and abnormal angiogenesis. Nephropathy is driven by glomerular hyperfiltration, mesangial expansion, and progressive fibrosis, often culminating in chronic kidney disease and albuminuria. Diabetic neuropathy involves peripheral nerve dysfunction and autonomic impairment, which can manifest as distal symmetric polyneuropathy, pain, numbness, and increased risk of foot ulcers.
Macrovascular disease increases risk of coronary artery disease, ischemic stroke, and peripheral arterial disease. Mechanistically, hyperglycemia accelerates atherosclerosis through glycation of lipoproteins, endothelial dysfunction, dysregulated coagulation, and chronic inflammation. Importantly, cardiovascular risk management is integral to diabetes care and extends beyond glucose control.
Therapeutic goals balance glycemic control with minimizing hypoglycemia and addressing comorbidities. For type 2 diabetes, lifestyle interventions—medical nutrition therapy, physical activity, weight reduction when appropriate, and smoking cessation—substantially improve insulin sensitivity and metabolic parameters. Pharmacologic treatment commonly begins with metformin unless contraindicated. Additional agents are selected based on patient-specific factors including cardiovascular disease, kidney function, weight considerations, and hypoglycemia risk. Options include GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and insulin. SGLT2 inhibitors reduce renal glucose reabsorption, lower intraglomerular pressure, and have demonstrated cardiovascular and renal benefits in many populations. GLP-1 receptor agonists improve glycemic control and often support weight loss, with evidence for cardiovascular risk reduction in high-risk patients.
For type 1 diabetes, insulin is mandatory. Modern regimens include basal-bolus injections or insulin pump therapy. Continuous glucose monitoring can reduce hypoglycemia exposure and improve time-in-range metrics. Education on carbohydrate counting, sick-day rules, ketone monitoring, and hypoglycemia management is crucial to prevent acute complications.
Acute emergencies include hypoglycemia (particularly with insulin and insulin secretagogues) and diabetic ketoacidosis or hyperosmolar hyperglycemic state. Hypoglycemia can present with tremor, sweating, confusion, and in severe cases, seizures or loss of consciousness. Prompt recognition and treatment (fast-acting carbohydrate for alert patients; glucagon or intravenous dextrose for severe cases) are life-saving.
A central principle in diabetes care is that outcomes depend on sustained metabolic control and comprehensive risk reduction. Evidence consistently shows that lowering blood glucose reduces microvascular complications, while overall cardiovascular benefit is achieved through integrated management of lipids, blood pressure, smoking status, and antiplatelet therapy when indicated. Because individual response varies, care should be personalized and guided by clinical guidelines and laboratory monitoring.
It is also important to interpret health claims about individual cases cautiously. Diabetes is a chronic disease with heterogeneous trajectories influenced by baseline physiology, access to care, adherence to therapy, genetics, comorbid conditions, and measurement variability. Low-potassium findings, for example, may reflect medication effects, nutritional status, renal handling, or endocrine shifts, but they do not negate the systemic pathophysiology of diabetes. Overall, the most reliable approach is evidence-based diagnosis and longitudinal management aimed at preventing both acute decompensation and long-term end-organ damage.
Source: White_RunnerOuO (Original post on X)
White_Runner: @scopuly @Rainmaker1973 Liar, too many fat people and with diabetes proves the opposite. Also, the guy chugging 7 liters of coke zero a day for 10 years and only presenting with low potassium in blood doing a full recovery, proves the opposite as well lmao ☠️. #breaking
— @White_RunnerOuO May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
